Allogene

Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance SOUTH SAN FRANCISCO, Calif., March 01, 2022…

• Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of…

• Allogene a déclaré que l'anomalie chromosomique n'était pas le résultat de la technologie TALEN® ou de son processus de fabrication • Allogene prévoit d’initier un essai clinique pivot…

 ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved…

ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma PatientsPhase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the…